clinical trial · NCT00412893
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
AspergillosisInvasive Fungal InfectionIsavuconazoleVoriconazole
brief summary
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
started
Mar 7, 2007
primary completion
Mar 28, 2013
completion
Mar 28, 2013
last updated
Dec 10, 2024
detailed description
Acute invasive fungal infections caused by aspergillus, zygomycetes and other filamentous fungi remain life threatening diseases. Early treatment with highly effective anti-fungals reduces mortality. This study investigates the efficacy and safety of isavuconazole in the treatment of invasive fungal diseases, caused by Aspergillus or other filamentous fungi.
official title
A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol